← boardnext 2026-09next 2026-11next 2026-12-30next 2027-01-30next 2027-03-31next 2027-12
SVA
Sinovac Life Sciences Co., Ltd.distress 0/10 · well-funded / low risk$6.470%today0% from 52w high
Infectious Disease 1
Lead: Epidemic Meningitis
Revenue
$386M
Liquidity
$6484M
Runway
12.7 yrs
Shares 1y
0%
Price & events
+0.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
+0.0%
6M
—
1Y
—
2Y
—
5Y
+0.0%
All
Overview
- Market Cap
- $464.94M
- Enterprise Value
- $471.55M
- Volume
- 0
- 52 Week Range
- $6.47 – $6.47
- Total Shares
- 71.86M
Pipeline stages · 9 programs
Sinovac PCV13, Prevenar 13™
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
experimental vaccine, Active Comparator vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Rabies Vaccine (Serum-free Vero Cell), Freeze-dried, Verorab®
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Rabies vaccine, Verorab®
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SNA02-48, Human tetanus immunoglobulin (HTIG)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Sabin Strain Inactivated Poliovirus Vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SNA02-48, HTIG, Tetanus Toxoid
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Low-dose RSV mRNA vaccine, High-dose RSV mRNA vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 17 trials · 11 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Sinovac PCV24, Prevnar® | Pneumococcal Infectious Disease | — | recruiting |
| 2026-09-30 Estimated 50% readout ~2026-12-14 | Phase 3 | Sinovac rabies vaccine | Rabies (Healthy Volunteers) | — | not yet recruiting |
| 2026-11 Estimated 50% readout ~2027-01-15 | Phase 3 | experimental vaccine, active comparator vaccine | Epidemic Meningitis, Meningococcal Vaccines | — | not yet recruiting |
| 2026-12-30 Estimated 50% readout ~2027-03-15 | Phase 3 | Rabies Vaccine (Serum-free Vero Cell), Freeze-dried, Verorab® | Rabies | — | not yet recruiting |
| 2027-01 Estimated 50% readout ~2027-03-17 | Phase 3 | experimental vaccine, Active Comparator vaccine | Epidemic Meningitis, Meningococcal Vaccines | — | not yet recruiting |
Show all 17 trials · 12 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01-30 Estimated 50% readout ~2027-04-15 | Phase 3 | Rabies vaccine, Verorab® | Rabies (Healthy Volunteers) | — | not yet recruiting |
| 2027-03-31 Estimated 50% readout ~2027-06-14 | Phase 3 | SNA02-48, Human tetanus immunoglobulin (HTIG) | Tetanus | — | not yet recruiting |
| 2027-04 Estimated 50% readout ~2027-06-15 | Phase 3 | experimental vaccine, Active Comparator vaccine | Epidemic Meningitis, Meningococcal Vaccines | — | not yet recruiting |
| 2027-04 Estimated 50% readout ~2027-06-15 | Phase 3 | experimental vaccine, Active Comparator vaccine | Epidemic Meningitis, Meningococcal Vaccines | — | not yet recruiting |
| 2027-07 Estimated 50% readout ~2027-09-14 | Phase 3 | Sinovac PCV13, Prevenar 13™ | Pneumococcal Infectious Diseases | — | not yet recruiting |
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) | Hand, Foot, and Mouth Disease(HFMD), Herpangina | — | not yet recruiting |
| 2026-06-30 | Phase 1 | Low-dose RSV mRNA vaccine, High-dose RSV mRNA vaccine | RSV, mRNA Vaccine | 60 | not yet recruiting |
| 2026-06 | Phase 1 | Sinovac PCV24, Prevnar® | Pneumococcal Infectious Disease | 180 | recruiting |
| 2025-12-08 | Phase 1/2 | SNA02-48, HTIG, Tetanus Toxoid | Tetanus | — | completed |
| 2025-11-30 | Phase 3 | bivalent enterovirus vaccine (Vero cell), inactivated, Enterovirus Type 71 Vaccine (Vero C | Hand, Foot, and Mouth Disease（HFMD) | 8000 | recruiting |
| 2025-06-25 | Phase 1 | Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13® | Pneumococcal Infectious Disease | — | completed |
| 2025-02-13 | Phase 3 | Sabin Strain Inactivated Poliovirus Vaccine | Poliomyelitis, Polio | 1442 | completed |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 71,860,702 · 0 offerings/1y · 0 PIPEs
- 2024-09-12SC 13D/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $4 (-46% upside) · 6 analysts
- no recent rating changes
Competitors — Epidemic Meningitis
- none identified
Recent news
- 2026-07-15Sinovac Biotech (NASDAQ: SVA) extends $55 per share dividend deadline - Stock Titan
- 2026-07-15SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend - STT Info
- 2026-07-07Price to sales forward of Sinovac Biotech, Ltd. – NASDAQ:SVA - TradingView
- 2026-06-19Sinovac Biotech Ltd (SVA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
- 2026-06-19Sinovac Biotech Ltd (SVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
- 2026-06-17Sinovac Biotech Ltd (SVA) Institutional Confidence - TradingKey
- 2026-06-17Sinovac Biotech Ltd (SVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
- 2026-06-15Nasdaq compliance restored for Sinovac as hearing is canceled - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.